Several other equities analysts have also weighed in on the stock. Bryan, Garnier & Co raised shares of AstraZeneca to a “buy” rating and raised their price objective for the company from GBX 7,700 ($100.61) to GBX 7,950 ($103.88) in a research report on Monday, November 25th. Credit Suisse Group set a GBX 7,300 ($95.39) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Friday, October 25th. Citigroup restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price target on shares of AstraZeneca and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Kepler Capital Markets lifted their price objective on shares of AstraZeneca from GBX 7,700 ($100.61) to GBX 8,000 ($104.53) and gave the company a “buy” rating in a research note on Tuesday, October 29th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of GBX 7,585.67 ($99.12).
Shares of LON AZN opened at GBX 7,229 ($94.46) on Friday. The stock has a market cap of $94.84 billion and a price-to-earnings ratio of 45.35. The business has a 50 day simple moving average of GBX 7,289.86 and a 200 day simple moving average of GBX 6,844.50. AstraZeneca has a 52 week low of GBX 109.51 ($1.43) and a 52 week high of GBX 8,227.88 ($107.51). The company has a debt-to-equity ratio of 148.59, a quick ratio of 0.70 and a current ratio of 0.92.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Shanghai Stock Exchange Composite Index
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.